TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs

Orchestra BioMed Holdings Inc. (NASDAQ:OBIO) is one of the best biotech penny stocks to buy according to analysts. On December 10, TD Cowen analyst Joshua Jennings initiated coverage of Orchestra BioMed with a Buy rating and $15 price target. TD Cowen believes that Orchestra BioMed is at the leading edge of cardiovascular device innovation. Its royalty-based model is anchored by two key programs: AVIM for hypertension and Virtue SAB for atherosclerotic disease, both of which target massive market gaps. With blue-chip partners and high-margin potential, the company is approaching critical data and commercialization milestones that could prove transformative.

The company is currently advancing two high-impact pivotal programs. Enrollment officially initiated for the Virtue Trial as of Q3 2025, which is a US registrational study comparing Virtue SAB head-to-head against the commercially available AGENT paclitaxel-coated balloon for treating coronary in-stent restenosis. Orchestra BioMed Holdings Inc. (NASDAQ:OBIO) remains in full operational control of this trial, with enrollment completion targeted for mid-2027. Simultaneously, the company is progressing its BACKBEAT global pivotal study for Atrioventricular Interval Modulation/AVIM Therapy. Recent FDA-approved protocol enhancements have expanded the enrollment criteria for BACKBEAT, increasing the eligible patient pool more than 24-fold, with enrollment completion expected in mid-2026.

TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs

Orchestra BioMed Holdings Inc. (NASDAQ:OBIO recently expanded its partnership with Medtronic, establishing a development pathway for AVIM Therapy-enabled leadless pacemakers. While Terumo holds a ROFR for certain transactions, Orchestra BioMed retains all development and distribution rights for Virtue SAB across all indications.

Orchestra BioMed Holdings Inc. (NASDAQ:OBIO) operates as a biomedical company in the US. It collaborates with Medtronic for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients, and with Terumo Corporation and Terumo Medical Corporation for developing and commercializing Virtue SAB for the treatment of coronary and peripheral artery disease.

While we acknowledge the potential of OBIO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than OBIO and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.